Cargando…
Non-homologous End Joining Inhibitor SCR-7 to Exacerbate Low-dose Doxorubicin Cytotoxicity in HeLa Cells
Among the genotoxic drug regimens, doxorubicin (DOX) is known for its high-dose side effects in several carcinomas, including cervical cancer. This study reports on testing the combined use of a DOX genotoxic drug and SCR-7 non-homologous end joining (NHEJ) inhibitor for HeLa cells. An in vitro DNA...
Autores principales: | Kumar, Ajay, Bhatkar, Devyani, Jahagirdar, Devashree, Sharma, Nilesh Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Cancer Prevention
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380189/ https://www.ncbi.nlm.nih.gov/pubmed/28382286 http://dx.doi.org/10.15430/JCP.2017.22.1.47 |
Ejemplares similares
-
Induction of Apoptotic Death and Cell Cycle Arrest in HeLa Cells by Extracellular Factors of Breast Cancer Cells
por: Jahagirdar, Devashree, et al.
Publicado: (2018) -
The spatial organization of non-homologous end joining: From bridging to end joining
por: Ochi, Takashi, et al.
Publicado: (2014) -
Natural and artificial small RNAs: a promising avenue of nucleic acid therapeutics for cancer
por: Yadav, Sunny, et al.
Publicado: (2017) -
Export of microRNAs: A Bridge between Breast Carcinoma and Their Neighboring Cells
por: Jahagirdar, Devashree, et al.
Publicado: (2016) -
SCR7, a potent cancer therapeutic agent and a biochemical inhibitor of nonhomologous DNA end‐joining
por: Manjunath, Meghana, et al.
Publicado: (2021)